CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Blueprint Medicines Corp. (BPMC) on Thursday reported a loss of $50 million in its fourth quarter.
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 79 cents.
The results fell short of Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for a loss of 70 cents per share.
The cancer drug developer posted revenue of $146.4 million in the period, which also missed Street forecasts. Ten analysts surveyed by Zacks expected $147.5 million.
For the year, the company reported that its loss narrowed to $67.1 million, or $1.07 per share. Revenue was reported as $508.8 million.
Blueprint Medicines shares have risen 19% since the beginning of the year. The stock has increased 34% in the last 12 months.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BPMC at https://www.zacks.com/ap/BPMC
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.